Sistema de Salut de Catalunya
Institut Català de la Salut
[Picchio CA, Araujo SG, Fernández E] Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain. [Nomah DK] Department of Health, Center for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS in Catalonia (CEEISCAT), Generalitat of Catalonia, Badalona, Spain. [Rando-Segura A] Unitat de Patologia Hepàtica, Servei de Bioquímica i Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Buti M] CIBER Hepatic and Digestive Diseases (CIBERehd), Instituto Carlos III, Madrid, Spain. Unitat del Fetge, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Rodríguez-Frías F] Unitat de Patologia Hepàtica, Servei de Bioquímica i Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER Hepatic and Digestive Diseases (CIBERehd), Instituto Carlos III, Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-05-02T13:05:09Z
2022-05-02T13:05:09Z
2021-08-25
Epidemiology; Health services; Viral hepatitis
Epidemiologia; Serveis de salut; Hepatitis viral
Epidemiología; Servicios de salud; Hepatitis viral
Chronic hepatitis B virus (HBV) infection is a major public health threat for migrant populations in Spain and efforts to scale up testing are needed to reach the WHO elimination targets. The Hepatitis B Virus Community Screening and Vaccination in Africans (HBV-COMSAVA) study aims to use point-of-care testing and simplified diagnostic tools to identify, link to care, or vaccinate African migrants in Barcelona during the COVID-19 pandemic. From 21/11/20 to 03/07/2021, 314 study participants were offered HBV screening in a community clinic. Rapid tests for HBsAg screening were used and blood samples were collected with plasma separation cards. Patients received results and were offered: linkage to specialist care; post-test counselling; or HBV vaccination in situ. Sociodemographic and clinical history were collected and descriptive statistics were utilized. 274 patients were included and 210 (76.6%) returned to receive results. The HBsAg prevalence was 9.9% and 33.2% of people had evidence of past resolved infection. Overall, 133 required vaccination, followed by post-test counselling (n = 114), and linkage to a specialist (n = 27). Despite the COVID-19 pandemic, by employing a community-based model of care utilizing novel simplified diagnostic tools, HBV-COMSAVA demonstrated that it was possible to diagnose, link to care, and vaccinate African migrants in community-based settings.
This study was carried out by ISGlobal with competitive funding through the Gilead Sciences global HBV-CARE program (IN-ES-988–5799).
Article
Published version
English
Emigració i immigració; Hepatitis B - Diagnòstic; Química clínica; HEALTH CARE::Health Services Administration::Patient Care Management::Point-of-Care Systems::Point-of-Care Testing; DISEASES::Virus Diseases::DNA Virus Infections::Hepadnaviridae Infections::Hepatitis B::Hepatitis B, Chronic; Other subheadings::Other subheadings::/diagnosis; NAMED GROUPS::Persons::Emigrants and Immigrants; ATENCIÓN DE SALUD::administración de los servicios de salud::gestión de la atención al paciente::sistemas de atención en la cabecera del paciente::análisis de diagnóstico inmediato; ENFERMEDADES::virosis::infecciones por virus ADN::infecciones por Hepadnaviridae::hepatitis B::hepatitis B crónica; Otros calificadores::Otros calificadores::/diagnóstico; DENOMINACIONES DE GRUPOS::personas::emigrantes e inmigrantes
Nature Research
Scientific Reports;11
https://doi.org/10.1038/s41598-021-96350-3
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
